Skip to search formSkip to main contentSkip to account menu

omadacycline

Known as: (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-9-{[(2,2-dimethylpropyl)amino]methyl}- 3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2- carboxamide 
National Institutes of Health

Related topics

Related topics

1 relation
Omadacycline:Susc:Pt:Isolate:OrdQn:MIC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
736. The Use of Bacteriophages to Inhibit Different Strains of Vancomycin-Resistant or Susceptible Enterococci
Abstract Background Vancomycin-resistant Enterococci (VRE) is a well-known infectious complication among immunocompromised… 
2019
2019
733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
Abstract Background OMC, an aminomethylcycline structurally related to tetracycline agents, was recently approved by the US FDA… 
2019
2019
Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants.
Review
2018
Review
2018
Return of the tetracyclines: omadacycline, a novel aminomethylcycline antimicrobial.
Omadacycline is a novel aminomethylcycline antimicrobial agent that is available in both oral and intravenous formulations. The… 
2018
2018
Omadacycline, a Magic Antibiotics for Bacterial Infections
©This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http… 
2018
2018
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials.
ABSSSI = acute bacterial skin and skin structure infections; ECR = early clinical response; EMA = European Medicines Agency; FDA… 
2018
2018
Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
Background Omadacycline is an oral and intravenous (IV) once-daily aminomethylcycline antibiotic that was recently approved by… 
2017
2017
Efficacy and Safety of Omadacycline in Intravenous Drug Using (IVDU) and Hepatitis C-Positive (HCV+) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis…
ACKNOWLEDGMENTS REFERENCES • Omadacycline (OMC), the first aminomethylcycline antibiotic to reach late-stage clinical development… 
Review
2015
Review
2015
[New antibacterial agents on the market and in the pipeline].
After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of… 
Review
2014
Review
2014
New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections
Introduction: Despite available treatment options for methicillin-resistant Staphylococcus aureus (MRSA), the morbidity and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)